• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

George D. Demetri, MD

Publications

  • Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ.Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.Eur J Cancer. 2014 Jun 12.
    24930624
  • George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG.Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.Cancer. 2014 Jun 12.
    24923260
  • Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD.Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care.Oncologist. 2014 Jun;19(6):669-680.
    24821824
  • Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, Fox EA, Antonescu CR, Fletcher CD, Guo X, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA.Dystrophin is a tumor suppressor in human cancers with myogenic programs.Nat Genet. 2014 Jun;46(6):601-6.
    24793134
  • Sioletic S, Czaplinski J, Hu L, Fletcher JA, Fletcher CD, Wagner AJ, Loda M, Demetri GD, Sicinska ET, Snyder EL.c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.J Pathol. 2014 May 22.
    24852265
  • Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA.KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.J Clin Oncol. 2014 Mar 31.
    24687822
  • Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, Dematteo RP.Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial.J Clin Oncol. 2014 Mar 17.
    24638003
  • George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C.Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.Cancer. 2014 Mar 1;120(5):738-43.
    24222211
  • Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH.Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.Eur J Cancer. 2014 Mar;50(5):981-6.
    24388774
  • Tomasetti C, Demetri GD, Parmigiani G.Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.F1000Res. 2013;2:152.
    24555070
  • Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD.A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.Clin Cancer Res. 2013 Nov 1;19(21):6020-9.
    24045182
  • Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J, Demetri GD.Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2013 Nov;14(12):1175-82.
    24140183
  • DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K, .Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.Ann Surg. 2013 Sep;258(3):422-9.
    23860199
  • Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.J Clin Oncol. 2013 Sep 10;31(26):3182-90.
    23775962
  • Zhang YX, van Oosterwijk JG, Sicinska E, Moss S, Remillard SP, van Wezel T, Bühnemann C, Hassan AB, Demetri GD, Bovée JV, Wagner AJ.Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.Clin Cancer Res. 2013 Jul 15;19(14):3796-807.
    23714727
  • Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY.Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.J Clin Oncol. 2013 Jul 1;31(19):2485-92.
    23715582
  • Hollebecque A, Postel-Vinay S, Verweij J, Demetri GD, Flaherty K, Bedard P, Soria JC.Modifying phase I methodology to facilitate enrolment of molecularly selected patients.Eur J Cancer. 2013 May;49(7):1515-20.
    23333057
  • Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, .Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet. 2013 Jan 26;381(9863):295-302.
    23177515
  • Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD.A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.Cancer. 2012 Nov 1;118(21):5403-13.
    22570147
  • Cesne AL, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD.A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.Eur J Cancer. 2012 Nov;48(16):3036-44.
    22749255
  • de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M, Heinrich MC, Tap W, Wang Q, Demetri G, George S, Humphreys BD.Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.Am J Hypertens. 2012 Oct;25(10):1118-23.
    22785409
  • George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.J Clin Oncol. 2012 Jul 1;30(19):2401-7.
    22614970
  • McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD, Blanke CD, von Mehren M, Brennan MF, McCall L, Ota DM, DeMatteo RP, .Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.J Am Coll Surg. 2012 Jul;215(1):53-9; discussion 59-60.
    22726733
  • Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PG.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Clin Cancer Res. 2012 Jun 1;18(11):3170-9.
    22661587
  • Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD.Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial.Cancer. 2012 May 17.
    22605650
  • Demetri GD.Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.Semin Oncol. 2011 Apr;38 Suppl 1:S10-9.
    21419931
  • Blay JY, Demetri GD.The evolution of a revolutionary class: extending benefits of tyrosine kinase inhibitors--introduction.Semin Oncol. 2011 Apr;38 Suppl 1:S1-2.
    21419930
  • Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S.Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.Clin Cancer Res. 2011 Feb 15;17(4):871-9.
    21177764
  • Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, Lai AH, Kelly L, Hornick JL, , O'Sullivan M, de Krijger RR, Dinjens WN, Demetri GD, Antonescu CR, Fletcher JA, Helman L, Stratakis CA.Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):314-8.
    21173220
  • Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Cancer Res. 2010 Dec 15;70(24):10038-43.
    21030459
  • Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.N Engl J Med. 2010 Oct 28;363(18):1727-33.
    20979472
  • Demetri GD.Disease state awareness in sarcoma.Clin Adv Hematol Oncol. 2010 Aug;8(8):543-5.
    20966890
  • Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA.Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.Int J Cancer. 2010 Dec 1;127(11):2718-22.
    20162573
  • Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, Delaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J.Soft tissue sarcoma.J Natl Compr Canc Netw. 2010 Jun;8(6):630-74.
    20581298
  • Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ.Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71. Review.
    19967539
  • Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4.
    20457867
  • Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, Ligon AH, Antonescu CR, Ramaiya NH, Demetri GD, Kwiatkowski DJ, Maki RG.Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.J Clin Oncol. 2010 Feb 10;28(5):835-40.
    20048174
  • Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, Butrynski JE, Fletcher CD, Demetri GD, Bertagnolli MM.Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.Ann Surg Oncol. 2010 Feb;17(2):407-15.
    19898902
  • Rubin BP, Blanke CD, Demetri GD, Dematteo RP, Fletcher CD, Goldblum JR, Lasota J, Lazar A, Maki RG, Miettinen M, Noffsinger A, Washington MK, Krausz T, .Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.Arch Pathol Lab Med. 2010 Feb;134(2):165-70.
    20121601
  • Theman TA, Hartzell TL, Sinha I, Polson K, Morgan J, Demetri GD, Orgill DP, George S.Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.J Clin Oncol. 2009 Nov 20;27(33):e198-200. Review.
    19805684
  • Ganjoo KN, Demetri GD, Jacobs C, Patel S.Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.Leuk Lymphoma. 2009 Nov;50(11):1882-4.
    19883316
  • Raut CP, Nucci MR, Wang Q, Manola J, Bertagnolli MM, Demetri GD, Morgan JA, Muto MG, Fletcher CD, George S.Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.Eur J Cancer. 2009 Nov;45(16):2818-24.
    19647426
  • Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR.Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.Clin Cancer Res. 2009 Oct 1;15(19):6232-40.
    19789325
  • Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD.Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.Clin Cancer Res. 2009 Sep 15;15(18):5869-77.
    19737953
  • Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG.Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.Clin Cancer Res. 2009 Sep 15;15(18):5902-9.
    19737946
  • Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P.A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.Clin Cancer Res. 2009 Sep 15;15(18):5910-6.
    19723647
  • Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A.Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.J Clin Oncol. 2009 Sep 1;27(25):4188-96.
    19652065
  • Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, Demetri GD, Joensuu H, Schöffski P, Poveda A.Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.Semin Oncol. 2009 Aug;36(4):302-11.
    19664491
  • Demetri GD,Wang Y,Wehrle E,Racine A,Nikolova Z,Blanke CD,Joensuu H,von Mehren M.Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors.J Clin Oncol. 2009 Jul 1;27(19):3141-7.
    19451435
  • George S,Merriam P,Maki RG,Van den Abbeele AD,Yap JT,Akhurst T,Harmon DC,Bhuchar G,O'Mara MM,D'Adamo DR,Morgan J,Schwartz GK,Wagner AJ,Butrynski JE,Demetri GD,Keohan ML.Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas.J Clin Oncol. 2009 Jul 1;27(19):3154-60.
    19451429
  • Demetri GD.Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST.Clin Adv Hematol Oncol. 2009 Feb;7(2):S6-7.
    19391310
  • Dematteo RP,Ballman KV,Antonescu CR,Maki RG,Pisters PW,Demetri GD,Blackstein ME,Blanke CD,von Mehren M,Brennan MF,Patel S,McCarter MD,Polikoff JA,Tan BR,Owzar K.Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Lancet. 2009 Mar 28;373(9669):1097-104.
    19303137
  • Gajiwala KS,Wu JC,Christensen J,Deshmukh GD,Diehl W,DiNitto JP,English JM,Greig MJ,He YA,Jacques SL,Lunney EA,McTigue M,Molina D,Quenzer T,Wells PA,Yu X,Zhang Y,Zou A,Emmett MR,Marshall AG,Zhang HM,Demetri GD.KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
    19164557
  • Winer E,Gralow J,Diller L,Karlan B,Loehrer P,Pierce L,Demetri G,Ganz P,Kramer B,Kris M,Markman M,Mayer R,Pfister D,Raghavan D,Ramsey S,Reaman G,Sandler H,Sawaya R,Schuchter L,Sweetenham J,Vahdat L,Schilsky RL.Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.J Clin Oncol. 2009 Feb 10;27(5):812-26.
    19103723
  • Quek R,Morgan JA,George S,Butrynski JE,Polson K,Meyer F,Demetri GD,Block SD.Small molecule tyrosine kinase inhibitor and depression.J Clin Oncol. 2009 Jan 10;27(2):312-3.
    19064960
  • Jiang X,Zhou J,Yuen NK,Corless CL,Heinrich MC,Fletcher JA,Demetri GD,Widlund HR,Fisher DE,Hodi FS.Imatinib targeting of KIT-mutant oncoprotein in melanoma.Clin Cancer Res. 2008 Dec 1;14(23):7726-32.
    19047099
  • Baker LH,Rowinsky EK,Mendelson D,Humerickhouse RA,Knight RA,Qian J,Carr RA,Gordon GB,Demetri GD.Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.J Clin Oncol. 2008 Dec 1;26(34):5583-8.
    18981463
  • Heinrich MC,Maki RG,Corless CL,Antonescu CR,Harlow A,Griffith D,Town A,McKinley A,Ou WB,Fletcher JA,Fletcher CD,Huang X,Cohen DP,Baum CM,Demetri GD.Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.J Clin Oncol. 2008 Nov 20;26(33):5352-9.
    18955458
  • Heinrich MC,Owzar K,Corless CL,Hollis D,Borden EC,Fletcher CD,Ryan CW,von Mehren M,Blanke CD,Rankin C,Benjamin RS,Bramwell VH,Demetri GD,Bertagnolli MM,Fletcher JA.Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.J Clin Oncol. 2008 Nov 20;26(33):5360-7.
    18955451
  • Eisenberg BL,Harris J,Blanke CD,Demetri GD,Heinrich MC,Watson JC,Hoffman JP,Okuno S,Kane JM,von Mehren M.Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.J Surg Oncol. 2009 Jan 1;99(1):42-7.
    18942073
  • Girnun GD,Chen L,Silvaggi J,Drapkin R,Chirieac LR,Padera RF,Upadhyay R,Vafai SB,Weissleder R,Mahmood U,Naseri E,Buckley S,Li D,Force J,McNamara K,Demetri G,Spiegelman BM,Wong KK.Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.Clin Cancer Res. 2008 Oct 15;14(20):6478-86.
    18927287
  • Haining WN,Davies J,Kanzler H,Drury L,Brenn T,Evans J,Angelosanto J,Rivoli S,Russell K,George S,Sims P,Neuberg D,Li X,Kutok J,Morgan J,Wen P,Demetri G,Coffman RL,Nadler LM.CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.Clin Cancer Res. 2008 Sep 1;14(17):5626-34.
    18765557
  • Bertagnolli MM,Morgan JA,Fletcher CD,Raut CP,Dileo P,Gill RR,Demetri GD,George S.Multimodality treatment of mesenteric desmoid tumours.Eur J Cancer. 2008 Nov;44(16):2404-10.
    18706807
  • Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG.Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases.Clin Cancer Res. 2008 May 1;14(9):2717-2725.
    18451237
  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE.Major response to imatinib mesylate in KIT-mutated melanoma.J Clin Oncol. 2008 Apr 20;26(12):2046-51.
    18421059
  • Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD.A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.Journal of the National Cancer Institute. 2008 Feb 20;100(4):282-4.
    18270341
  • Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H.Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.J Clin Oncol. 2008 Feb 1;26(4):620-5.
    18235121
  • Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA.Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.Cancer Treat Rev. 2008 May;34(3):223-230.
    18234424
  • Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.J Clin Oncol. 2008 Feb 1;26(4):626-32.
    18235122
  • Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W Jr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS.Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.J Clin Oncol. 2008 Jan 10;26(2):313-25.
    18086794
  • Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH.Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.Lancet. 2007 Dec 15;370(9604):2011-9.
    18083403
  • Demetri GD.Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.J Clin Invest. 2007 Dec;117(12):3650-3.
    18060025
  • Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD.CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.AJR Am J Roentgenol. 2007 Dec;189(6):W324-30.
    18029844
  • Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP.Leiomyosarcoma of the inferior vena cava: survival after aggressive management.Ann Surg Oncol. 2007 Dec;14(12):3534-41.
    17896156
  • Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA.KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.Oncogene. 2007 Sep 27;26(44):6386-95.
    17452978
  • Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD.Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5398-405.
    17875769
  • Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J.NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30. Review.
    17624289
  • Faivre S, Demetri G, Sargent W, Raymond E.Molecular basis for sunitinib efficacy and future clinical development.Nat Rev Drug Discov. 2007 Sep;6(9):734-45. Review.
    17690708
  • Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG.Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.Lancet Oncol. 2007 Jul;8(7):595-602.
    17586092
  • Bauer S, Duensing A, Demetri GD, Fletcher JA.KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.Oncogene. 2007 Nov 29;26(54):7560-8.
    17546049
  • Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, Deprimo SE, Shalinsky DR, Demetri GD, Heymach JV.Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor.Clin Cancer Res. 2007 May 1;13(9):2643-50.
    17473195
  • Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery .Corrigendum: High-throughput oncogene mutation profiling in human cancer.Nat Genet. 2007 Apr;39(4):567.
    17392811
  • Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S.Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas : results of a phase II trial.Cancer. 2007 Mar 23;109(9):1863-1869.
    17385194
  • Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA.High-throughput oncogene mutation profiling in human cancer.Nat Genet. 2007 Mar;39(3):347-351.
    17293865
  • Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee WK, Old LJ, Demetri GD, Wong KK.Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.J Clin Invest. 2007 Feb;117(2):346-52.
    17256054
  • Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK.Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.Ann Intern Med. 2006 Nov 7;145(9):660-4.
    17088579
  • Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.Lancet. 2006 Oct 14;368(9544):1329-38.
    17046465
  • Bauer S, Yu LK, Demetri GD, Fletcher JA.Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.Cancer Res. 2006 Sep 15;66(18):9153-61.
    16982758
  • Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G.Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret.Patient Educ Couns. 2006 Oct;63(1-2):104-9.
    16242898
  • Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA.Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.J Clin Oncol. 2006 Oct 10;24(29):4764-74.
    16954519
  • Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM.Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors.J Clin Oncol. 2006 May 20;24(15):2325-2331.
    16710031
  • George S, Desai J, Paul Eder J, Manola J, Ryan DP, Appleman LJ, Demetri GD.Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.Eur J Cancer. 2006 May;42(7):864-70.
    16503137
  • Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).J Clin Oncol. 2006 Mar 1;24(7):1195-203.
    16505440
  • Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ,.Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.J Clin Oncol. 2006 Jan 1;24(1):190-205.
    16326753
  • Rodgers GM, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Demetri GD, Djulbegovic B, Garst JL, Gore M, Kraut EH, Lin WC, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P.Cancer- and treatment-related anemia.J Natl Compr Canc Netw. 2005 Nov;3(6):772-89.
    16316613
  • Dileo P, Demetri GD.Update on new diagnostic and therapeutic approaches for sarcomas.Clin Adv Hematol Oncol. 2005 Oct;3(10):781-91.
    16258489
  • George S, Hornick JL, Bertagnolli MM, Fletcher CD, Demetri GD.Current management of metastatic gastrointestinal stromal tumor: a case report.Clin Adv Hematol Oncol. 2003 Jan;1(1):63-4; discussion 65.
    16227963
  • Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD.Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.J Clin Oncol. 2005 Aug 20;23(24):5484-92.
    16110008
  • Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK,.Myeloid growth factors clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2005 Jul;3(4):540-55.
    16038645
  • Griffin JM, Amand MS, Demetri GD.Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.Clin J Oncol Nurs. 2005 Apr;9(2):161-9.
    15853160
  • Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, Duensing A, van de Rijn M, Schnipper LE, Demetri GD.Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.J Clin Oncol. 2005 Apr 20;23(12):2735-43.
    15837988
  • Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD.Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.Radiology. 2005 Jun;235(3):892-8.
    15833985
  • Desai J, Demetri GD.Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.Best Pract Res Clin Haematol. 2005;18(3):389-406.
    15792913
  • Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD.Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.Ann Oncol. 2005 Apr;16(4):566-78.
    15781488
  • Oliveira AM, Perez-Atayde AR, Dal Cin P, Gebhardt MC, Chen CJ, Neff JR, Demetri GD, Rosenberg AE, Bridge JA, Fletcher JA.Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes.Oncogene. 2005 May 12;24(21):3419-26.
    15735689
  • Saund MS, Demetri GD, Ashley SW.Gastrointestinal stromal tumors (GISTs).Curr Opin Gastroenterol. 2004 Mar;20(2):89-94.
    15703627
  • McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA.Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.J Clin Oncol. 2005 Feb 1;23(4):866-73.
    15681532
  • Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD.Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.Clin Cancer Res. 2004 Sep 1;10(17):5732-40.
    15355900
  • Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.J Clin Oncol. 2003 Dec 1;21(23):4342-9.
    14645423
  • Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP.Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.Breast Cancer Res Treat. 2003 Jun;79(3):391-7.
    12846423
  • Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA.PDGFRA activating mutations in gastrointestinal stromal tumors.Science. 2003 Jan 31;299(5607):708-10.
    12522257
  • Demetri GD.Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.Hematol Oncol Clin North Am. 2002 Oct;16(5):1115-24.
    12512386
  • Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, Kuhlman C, Winkelman J, Merriam P, Quigley T, Jimeno J, Manola J, Demetri GD.A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.Oncologist. 2002;7(6):531-8.
    12490740
  • Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G.Management of malignant gastrointestinal stromal tumours.Lancet Oncol. 2002 Nov;3(11):655-64.
    12424067
  • Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS.A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.Cancer J. 2002 Sep-Oct;8(5):395-9.
    12416897
  • Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG.Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19.
    12357306
  • Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med. 2002 Aug 15;347(7):472-80.
    12181401
  • Demetri GD.ET-743: the US experience in sarcomas of soft tissues.Anticancer Drugs. 2002 May;13 Suppl 1:S7-9.
    12173492
  • Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy J.Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.Clin Breast Cancer. 2002 Apr;3(1):45-51.
    12020395
  • Glaspy J, Degos L, Dicato M, Demetri GD.Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.Oncologist. 2002;7(2):126-35.
    11961196
  • Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD.Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.Clin Cancer Res. 2002 Mar;8(3):670-8.
    11895894
  • Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD.Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.Clin Cancer Res. 2002 Feb;8(2):383-93.
    11839653
  • Brooks BJ, Bani JC, Fletcher CD, Demeteri GD.Challenges in oncology. Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571).J Clin Oncol. 2002 Feb 1;20(3):870-2.
    11821475
  • Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA.KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.Cancer Res. 2001 Nov 15;61(22):8118-21.
    11719439
  • Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD.STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.Oncogene. 2001 Aug 16;20(36):5054-8.
    11526490
  • Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD.Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.N Engl J Med. 2001 Apr 5;344(14):1052-6.
    11287975
  • Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.Bone Marrow Transplant. 2001 Feb;27(3):269-78.
    11277174
  • Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW.Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.Clin Cancer Res. 2001 Feb;7(2):231-42.
    11234874
  • Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5.
    10984506
  • Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA.KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.Am J Pathol. 2000 Mar;156(3):791-5.
    10702394
  • Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD.Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma.Cancer. 1999 Oct 15;86(8):1621-7.
    10526294
  • Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S.Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6.
    10097144
  • Demetri GD, Kris M, Wade J, Degos L, Cella D.Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.J Clin Oncol. 1998 Oct;16(10):3412-25.
    9779721
  • Demetri GD, Pollock R, Baker L, Balcerzak S, Casper E, Conrad C, Fein D, Hutchinson R, Schupak K, Spiro I, Wagman L.NCCN sarcoma practice guidelines. National Comprehensive Cancer Network.Oncology (Huntingt). 1998 Jul;12(7A):183-218.
    9699217
  • Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ.Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo.J Exp Med. 1996 Jun 1;183(6):2681-6.
    8676090
  • Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM.Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival.J Clin Oncol. 1996 Apr;14(4):1201-8.
    8648375
  • Demetri GD, Elias AD.Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.Hematol Oncol Clin North Am. 1995 Aug;9(4):765-85.
    7490240
  • Singer S, Corson JM, Demetri GD, Healey EA, Marcus K, Eberlein TJ.Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma.Ann Surg. 1995 Feb;221(2):185-95.
    7857146
  • Salgia R, Demetri GD, Kaplan WD.Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case rep.Cancer. 1994 Oct 1;74(7):1887-90.
    7521785
  • Demetri GD.The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer.Hematol Oncol Clin North Am. 1994 Feb;8(1):233-49.
    8150782
  • Demetri GD.Impact of hematopoietic growth factors on the management of small-cell lung cancer.Chest. 1993 Apr;103(4 Suppl):427S-432S.
    8384974
  • Demetri GD.Hematopoietic growth factors: current knowledge, future prospects.Curr Probl Cancer. 1992 Jul-Aug;16(4):177-259.
    1382921
  • Demetri GD, Griffin JD.Granulocyte colony-stimulating factor and its receptor.Blood. 1991 Dec 1;78(11):2791-808.
    1720034
  • Demetri GD, Ernst TJ, Pratt ES, Zenzie BW, Rheinwald JG, Griffin JD.Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes.J Clin Invest. 1990 Oct;86(4):1261-9.
    2212010
  • Sharkis SJ, Jones RJ, Bellis ML, Demetri GD, Griffin JD, Civin C, May WS.The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors.Blood. 1990 Aug 15;76(4):716-20.
    2200537
  • Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G.Tissue factor gene expression in acute myeloblastic leukemia.Thromb Res. 1989 Nov 1;56(3):425-30.
    2617479
  • Demetri GD, Spriggs DR, Sherman ML, Arthur KA, Imamura K, Kufe DW.A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo.J Clin Oncol. 1989 Oct;7(10):1545-53.
    2506316
  • Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD.Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.Blood. 1989 Aug 15;74(3):940-6.
    2787682
  • Brouckaert P, Spriggs DR, Demetri G, Kufe DW, Fiers W.Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma.J Exp Med. 1989 Jun 1;169(6):2257-62.
    2499657